Science & Tech Spotlight: Long COVID The broade
Post# of 1418
(Total Views: 258)
Posted On: 05/06/2022 3:42:38 PM
Science & Tech Spotlight: Long COVID
The broader public health, social, and economic effects of long COVID are unclear. Studies in the U.S. estimate that 10 to 30 percent of COVID-19 survivors develop long COVID. If so, 7.7 million to 23 million people in the U.S. may have developed long COVID as of February 2022. In January 2022, the Brookings Institution conducted a meta-analysis to suggest that long COVID may be responsible for over 1 million workers being out of the labor force at any given time."
https://www.gao.gov/products/gao-22-105666
That would be about 100M people worldwide
Let's pick a round number and say it's a grand to treat them.
That would put the market potential @ $100B for Long Covid right now, not including everyone that will have it in the future so that could be $50B a year
And, it would be very lucky IF it was only $1K. Heck, doctor visits, test, etc. would be over $1K if there wasn't a solution.
I do understand people's concern over $150 bottle that may be a solution, but at the same time some are out of work for months or years. Don't spend the $150 and let others go first and prove it out for you or wait until insurance picks it up.
There are innovators, early adopters, the early majority, the late majority and laggards with many products. No trophy for going first. No shame in going last.
I will add Todos timing is perfect. Better Long Covid is part of the valuation BEFORE the spinoff. So glad the company and board of directors don't get their strategic advice from message boards or twitter.
The broader public health, social, and economic effects of long COVID are unclear. Studies in the U.S. estimate that 10 to 30 percent of COVID-19 survivors develop long COVID. If so, 7.7 million to 23 million people in the U.S. may have developed long COVID as of February 2022. In January 2022, the Brookings Institution conducted a meta-analysis to suggest that long COVID may be responsible for over 1 million workers being out of the labor force at any given time."
https://www.gao.gov/products/gao-22-105666
That would be about 100M people worldwide
Let's pick a round number and say it's a grand to treat them.
That would put the market potential @ $100B for Long Covid right now, not including everyone that will have it in the future so that could be $50B a year
And, it would be very lucky IF it was only $1K. Heck, doctor visits, test, etc. would be over $1K if there wasn't a solution.
I do understand people's concern over $150 bottle that may be a solution, but at the same time some are out of work for months or years. Don't spend the $150 and let others go first and prove it out for you or wait until insurance picks it up.
There are innovators, early adopters, the early majority, the late majority and laggards with many products. No trophy for going first. No shame in going last.
I will add Todos timing is perfect. Better Long Covid is part of the valuation BEFORE the spinoff. So glad the company and board of directors don't get their strategic advice from message boards or twitter.
(1)
(0)